Research map: Chondrosarcoma: A comprehensive review of tumor biology, clinical behavior, and therapeutic advances

Back to the article

Papers in this map

  1. mTOR Signaling in Growth, Metabolism, and Disease · Robert A. Saxton · 2017 · 7778 citations · Cited by this paper
  2. Targeting key epigenetic regulators in solid tumors: focus on EZH2, PRMT5, and BET inhibitors · 2026 · Related
  3. PD-1 blockade induces responses by inhibiting adaptive immune resistance · Paul C. Tumeh · 2014 · 6779 citations · Cited by this paper
  4. Glioblastoma and resistance to radiotherapy: role of cancer stem cells subpopulations, hypoxia and therapeutic strategies · 2026 · Related
  5. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients · Roy S. Herbst · 2014 · 5363 citations · Cited by this paper
  6. Pharmacological prevention of second primary cancers: From chemoprevention to precision cancer interception · 2026 · Related
  7. Tumor mutational load predicts survival after immunotherapy across multiple cancer types · Robert M. Samstein · 2019 · 4457 citations · Cited by this paper
  8. Circulating tumor DNA in breast cancer: From technological foundation to clinical implementation · 2026 · Related
  9. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate · Lenny Dang · 2009 · 4216 citations · Cited by this paper
  10. Multigene assays in early breast cancer: Current evidence, limits and future directions · 2026 · Related
  11. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden · Zachary Rockow Chalmers · 2017 · 3804 citations · Cited by this paper
  12. Cyclotherapy: exploiting cell-cycle decoupling for selective cancer cytotoxicity and normal-tissue protection · 2026 · Related
  13. Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation · María E. Figueroa · 2010 · 2806 citations · Cited by this paper
  14. Cellular senescence: A novel mechanism of therapeutic resistance in prostate cancer · 2025 · Related
  15. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial · Winette T.A. van der Graaf · 2012 · 2125 citations · Cited by this paper
  16. Is Cytoreductive surgery for unresectable colorectal liver metastases able to improve patient outcome? Results of a pilot prospective study · 2026 · Related
  17. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer · Mario F. Fraga · 2005 · 1938 citations · Cited by this paper
  18. KRAS G12C-mutant non-small cell lung cancer: A practical guide for clinicians · 2026 · Related
  19. Indian hedgehog signaling regulates proliferation and differentiation of chondrocytes and is essential for bone formation · Benoit St‐Jacques · 1999 · 1771 citations · Cited by this paper
  20. Advances in Radiation Therapy for Primary Bone Malignancies · 2026 · Related
  21. The RB and p53 pathways in cancer · Charles J. Sherr · 2002 · 1706 citations · Cited by this paper
  22. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial · Hussein A. Tawbi · 2017 · 1480 citations · Cited by this paper
  23. An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells · Dan Rohle · 2013 · 1177 citations · Cited by this paper
  24. mTOR signalling and cellular metabolism are mutual determinants in cancer · Dirk Mossmann · 2018 · 1142 citations · Cited by this paper
  25. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours · Maria Fernanda Amary · 2011 · 1034 citations · Cited by this paper
  26. Src family kinases, key regulators of signal transduction · Sarah J. Parsons · 2004 · 953 citations · Cited by this paper
  27. p53 in the DNA-Damage-Repair Process · Ashley B. Williams · 2016 · 868 citations · Cited by this paper
  28. Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting · Liz J. Hernández Borrero · 2021 · 772 citations · Cited by this paper
  29. The Clinical Approach Towards Chondrosarcoma · Hans A. J. Gelderblom · 2008 · 758 citations · Cited by this paper
  30. Resection and reconstruction for primary neoplasms involving the innominate bone. · W F Enneking · 1978 · 758 citations · Cited by this paper
  31. Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study · Isabelle Ray‐Coquard · 2012 · 576 citations · Cited by this paper
  32. Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy · Silvia von Karstedt · 2017 · 568 citations · Cited by this paper
  33. From the Archives of the AFIP · Mark D. Murphey · 2003 · 542 citations · Cited by this paper
  34. Osteosarcoma, Chondrosarcoma, and Ewing's Sarcoma · Timothy A. Damron · 2007 · 539 citations · Cited by this paper
  35. Epigenetic Therapies for Cancer · Susan Elaine Bates · 2020 · 530 citations · Cited by this paper
  36. Proton radiation therapy for chordomas and chondrosarcomas of the skull base · Eugen Boris Hug · 1999 · 516 citations · Cited by this paper
  37. Bone cancers · Howard D. Dorfman · 1995 · 499 citations · Cited by this paper
  38. TRAIL signalling: Decisions between life and death · Christina Falschlehner · 2007 · 460 citations · Cited by this paper
  39. Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion · Kensuke Tateishi · 2015 · 454 citations · Cited by this paper

Source: OpenAlex (CC0)